Citation

Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J.: Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem, Volume 57 (10), 2014

Authors

Banner B, Conde-Knape K, Danzi S, Dvorozniak M, Haynes NE, Huang KS, Kelly MJ, Klein I, Larigan JD, Mennona F, Pietranico-Cole S, Qian Y, Reynolds CH, Scott N, So SS, Taub R, Thakkar K, Tilley J., Vermeulen J

Journal

J Med Chem

Year

2014

DOI

10.1021/jm4019299

PubMed

24712661

Machine-readable

REST APIRDF